Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: September 6, 2005
Last updated: July 13, 2006
Last verified: July 2006
Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

Condition Intervention Phase
Anxiety Neuroses
Drug: Pregabalin
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 1-Year Open-Label Safety Extension Study of Pregabalin in Patients With Anxiety Disorders

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Safety Tolerability

Estimated Enrollment: 511
Study Start Date: January 2001
Estimated Study Completion Date: March 2006

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have completed the double-blind portion of the preceding trial
  • Completed any protocol specified withdrawal phase and follow-up visits.

Exclusion Criteria:

  • Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00150449

  Show 142 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00150449     History of Changes
Other Study ID Numbers: 1008-100 
Study First Received: September 6, 2005
Last Updated: July 13, 2006
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders
Anti-Anxiety Agents
Calcium Channel Blockers
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Tranquilizing Agents processed this record on May 26, 2016